Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M; ESCMID Fungal Infection Study Group.

Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67. doi: 10.1111/1469-0691.12041.

2.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
3.

Patients at high risk of invasive fungal infections: when and how to treat.

Rüping MJ, Vehreschild JJ, Cornely OA.

Drugs. 2008;68(14):1941-62. Review.

PMID:
18778118
4.

Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.

Nachbaur D, Angelova O, Orth-Höller D, Ditlbacher A, Lackner M, Auberger J, Lass-Flörl C.

Eur J Haematol. 2015 Mar;94(3):258-64. doi: 10.1111/ejh.12426. Epub 2014 Sep 1.

PMID:
25082655
5.

EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.

Llinares P, Ruiz I, Zaragoza R, Ferrer R, Rodríguez AH, Maseda E, Grau S; EPICO PROJECT GROUP.

Rev Iberoam Micol. 2016 Oct - Dec;33(4):206-215. doi: 10.1016/j.riam.2016.06.002. Epub 2016 Oct 15.

PMID:
27751781
6.

Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines.

De Rosa FG, Motta I, Corcione S, Cattel F, Di Perri G, D'Avolio A.

Infez Med. 2014 Jun;22(2):107-11. Review.

7.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
8.

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group.

Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039.

9.

Antifungal treatment strategies in high risk patients.

Rüping MJ, Vehreschild JJ, Cornely OA.

Mycoses. 2008 Sep;51 Suppl 2:46-51. doi: 10.1111/j.1439-0507.2008.01572.x.

PMID:
18721331
10.

Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.

Gahn B, Schub N, Repp R, Gramatzki M.

Eur J Med Res. 2007 Aug 16;12(8):337-40.

PMID:
17933709
11.

Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.

Ziakas PD, Kourbeti IS, Mylonakis E.

Clin Ther. 2014 Feb 1;36(2):292-306.e1. doi: 10.1016/j.clinthera.2013.11.010. Epub 2014 Jan 17.

PMID:
24439393
12.

[Potential of anidulafungin in hematological patients].

Vázquez López L, Ruiz Camps I.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 14:44-50. Review. Spanish.

PMID:
19572434
13.

Anidulafungin: a new echinocandin with a novel profile.

Vazquez JA.

Clin Ther. 2005 Jun;27(6):657-73. Review.

PMID:
16117974
14.
15.

[Micafungin in invasive candidiasis among oncohematological patients].

Jarque I, Angel Sanz M.

Rev Iberoam Micol. 2009 Mar 31;26(1):75-7. doi: 10.1016/S1130-1406(09)70013-0. Epub 2009 May 7. Review. Spanish.

16.

Management of mycoses in surgical patients -- review of the literature.

Holzheimer RG, Dralle H.

Eur J Med Res. 2002 May 31;7(5):200-26. Review.

PMID:
12069912
17.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK.

Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Review.

PMID:
24563222
18.
19.

Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, Cornely OA.

Ann Hematol. 2014 Sep;93(9):1449-56. doi: 10.1007/s00277-014-2108-y. Epub 2014 Jun 21. Review.

PMID:
24951122
20.

Management of invasive mycoses in hematology patients: current approaches.

Perfect JR.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 7):5-14. Review.

Supplemental Content

Support Center